| Project/Area Number |
16591374
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Hyogo College of Medicine |
|---|
Principal Investigator |
YANAGI Hidenori Hyogo College of Medicine, Faculty of Medicine, Associate Professor, 医学部, 助教授 (50241170)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YOSHIKAWA Reigetsu Hyogo College of Medicine, Faculty of Medicine, Research Associate, 医学部, 助手 (90319864)
NODA Masafumi Hyogo College of Medicine, Faculty of Medicine, Research Associate, 医学部, 助手 (30309463)
YAMAMURA Takehira Hyogo College of Medicine, Faculty of Medicine, Professor, 医学部, 教授 (90068510)
HASHIMOTO Tomoko (TAMAOKI Tomoko) Hyogo College of Medicine, Faculty of Medicine, Professor, 医学部, 教授 (10172868)
OKAMURA Haruki Hyogo College of Medicine, Faculty of Medicine, Professor, 医学部, 教授 (60111043)
|
|---|
| Project Period (FY) |
2004 – 2005
|
| Project Status |
Completed (Fiscal Year 2005)
|
| Budget Amount *help |
¥3,600,000 (Direct Cost: ¥3,600,000)
Fiscal Year 2005: ¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 2004: ¥2,600,000 (Direct Cost: ¥2,600,000)
|
|---|
| Keywords | distant metastasis / colorectal cancer / polysaccharide-K(PSK) / integrated medicine / 化学療法 / 放射線療法 / 代替療法 |
|---|
| Research Abstract |
Distant metastasis is one of the major problems in treatment for advanced colorectal cancer. There is growing evidence that Polysaccharide-K (PSK), or Krestin (Sankyo Co., Tokyo, Japan), a mushroom ingredient, prevents distant metastases and improves survival rates by 10 to 20% in colorectal, gastric, esophageal, nasopharynx, lung, and breast cancers. We set out to investigate the possible role of PSK-related markers in predicting distant metastasis and the clinical outcome in colorectal cancer (CRC) patients. To screen PSK-related markers, we analyzed expression profiles using protein microarrays in a human colorectal adenocarcinoma cell line, SW480 with a mutant p53gene, and their clinical implication on the prognosis of CRC patients (n=35). We screened ECA39 protein, a direct target for c-Myc regulation, as a candidate relating to anti-metastatic effects of PSK. In immunohistochemistry, ECA39 was significantly expressed in the tumor tissues with distant metastases compared to the ones without metastases (p<0.00001). Positive ECA39 expression showed high reliability for the prediction of distant metastases (sensitivity : 86.7%, specificity : 90%, positive predictive value : 86.7%, and negative predictive value 90%). The cumulative 5-year disease free survival rate was 76% in the ECA39(-) group and 26% in the ECA39(+) group (p<0.05). Our results suggest that ECA39 is a dominant predictor of distant metastasis in patients with advanced CRC and may be useful for the application of immunotherapy by integrated medicine.
|
